R. Gelber

发表

Patterns of treatment effects in subsets of patients in clinical trials.

M. Bonetti, R. Gelber, 2004, Biostatistics.

The duration of a life of quality should become the focus of "quality-of-life" studies.

R. Gelber, A. Goldhirsch, M. Castiglione, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).

R. Gelber, A. Goldhirsch, C. Hürny, 1992, Journal of the National Cancer Institute. Monographs.

First--select the target: better choice of adjuvant treatments for breast cancer patients.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

R. Gelber, A. Goldhirsch, A. Coates, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.

M. Bonetti, R. Gelber, 2000, Statistics in medicine.

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

R. Gelber, A. Goldhirsch, J. Collins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

M. Dowsett, R. Gelber, J. Baselga, 2005, The New England journal of medicine.

MEASURING DISEASE: A REVIEW OF DISEASE‐SPECIFIC QUALITY OF LIFE MEASUREMENTS SCALES.

R. Gelber, 1996 .

Problems with the progesterone receptor in practice?

R. Gelber, V. Jordan, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

R. Gelber, A. Goldhirsch, A. Coates, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

James R. Anderson, R. Gelber, K. Cain, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, B. Cole, 1993, Controlled clinical trials.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2002, Journal of the National Cancer Institute.

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Thomas J. Smith, Michael A. Friedman, Harrison Ball, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design considerations for AIDS trials.

D P Byar, V De Gruttola, S B Green, 1990, The New England journal of medicine.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

R. Gelber, A. Goldhirsch, G. Viale, 2018, The Lancet. Oncology.

Present and future projects of the international breast cancer study group

J. Forbes, F. Cavalli, R. Gelber, 1994, Cancer.

Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer.

R. Gelber, A. Goldhirsch, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

R. Gelber, A. Goldhirsch, A. Coates, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

S. Lipsitz, S. Colan, R. Gelber, 2004, The New England journal of medicine.

Long-Term E nalapril T herapy f or L eft V entricular D ysfunction in D oxorubicin-Trea ted S urvivors o f C hildhood C ancer

S. Lipsitz, S. Colan, R. Gelber, 2002 .

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

S. Colan, R. Gelber, S. Sallan, 1991, The New England journal of medicine.

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.

S. Lipsitz, S. Colan, R. Gelber, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

R. Gelber, S. Sallan, L. Silverman, 2001, Blood.

Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update).

R. Gelber, S. Sallan, N. Tarbell, 1991, Blood.

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia.

R. Gelber, S. Sallan, J. Cassady, 1986, Medical and pediatric oncology.

Bony morbidity in children treated for acute lymphoblastic leukemia.

R. Gelber, S. Sallan, L. Silverman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia

R. Gelber, S. Sallan, L. Silverman, 2000, Cancer.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

David Cameron, Richard Bell, Mitch Dowsett, 2007, The Lancet.

Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy

R. Gelber, B. Gusterson, A. Goldhirsch, 2001, ANZ journal of surgery.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

R. Gelber, M. Piccart, G. Viale, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Patrick Neven, István Láng, A. Giobbie-Hurder, 2011, The Lancet. Oncology.

Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

R. Gelber, J. Baselga, H. Gómez, 2010 .

Adjuvant Therapy for Node-Negative Breast Cancer

I. Tannock, C. Redmond, R. Gelber, 1989 .

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 1998, Journal of Clinical Oncology.

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, A. Coates, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

R. Gelber, A. Goldhirsch, M. Regan, 2013, Breast.

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006, Journal of the National Cancer Institute.

Subsets within the chemotherapy overview

R. Gelber, A. Goldhirsch, A. Coates, 1998, The Lancet.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

P. Neven, R. Gelber, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

P. Neven, R. Gelber, H. Ditzel, 2012, Journal of the National Cancer Institute.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

E. Winer, S. Edge, T. Powles, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality adjusted survival analysis.

R. Gelber, R. Simes, P. Glasziou, 1990, Statistics in medicine.

Integration of Quality-of-Life Issues into Clinical Trials of Breast Cancer

R. Gelber, P. Glasziou, A. Goldhirsch, 1989 .

Analysis of survival by tumor response.

K C Cain, J R Anderson, R. Gelber, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

A. Giobbie-Hurder, R. Gelber, K. Price, 2009, Clinical trials.

Subsets within the chemotherapy overview. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 1998, Lancet.

The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

R. Gelber, C. Perez, L. Brady, 1980, International journal of radiation oncology, biology, physics.

Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials.

R. Gelber, R. Gelman, K. Cain, 1985, Cancer treatment reports.

Prediction of cancer outcome with microarrays

R. Gelber, A. Goldhirsch, G. Viale, 2005, The Lancet.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

J. Forbes, R. Gelber, G. Hortobagyi, 2015, The New England journal of medicine.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

R. Gelber, A. Goldhirsch, M. Regan, 2013, Breast.

Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

R. Gelber, R. Paridaens, A. Goldhirsch, 2010, Breast Cancer Research and Treatment.

Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?

R. Gelber, A. Goldhirsch, J. Ingle, 2009, Annals of Oncology.

What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?

R. Gelber, A. Goldhirsch, A. Coates, 2005, Nature Clinical Practice Oncology.

Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 2000, European journal of cancer.

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

R. Gelber, A. Coates, K. Price, 1999, The Lancet.

Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.

R. Gelber, E. Guinan, G. Longmore, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, E. Perez, 2014, The New England journal of medicine.

Adjuvant ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, The New England journal of medicine.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2007, British Journal of Cancer.

Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).

J. Forbes, R. Gelber, A. Goldhirsch, 1998, British Journal of Cancer.

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

R. Gelber, S. Loi, M. Piccart, 2019, Breast Cancer Research and Treatment.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group.

R. Gelber, K. Anderson, B. Cole, 1994, Biometrics.

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

R. Gelber, A. Goldhirsch, J. Ingle, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary Summary of the Consensus Discussion

J. Forbes, R. Gelber, H. Burstein, 2013 .

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

A. Giobbie-Hurder, R. Gelber, M. Regan, 2011, Breast Cancer Research.

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

R. Gelber, J. Baselga, B. Leyland-Jones, 2009 .

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009 .

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

R. Gelber, M. Gnant, A. Goldhirsch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

E. Winer, R. Gelber, S. Martino, 2018, The New England journal of medicine.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

J. Forbes, R. Gelber, G. Hortobagyi, 2015, The New England journal of medicine.

Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po

R. Gelber, H. Burstein, M. Regan, 2015 .

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival

B. F. Cole, R. Gray, R. Gelber, 1996, The Lancet.

Understanding adjuvant chemotherapy for breast cancer.

R. Gelber, A. Goldhirsch, 1994, New England Journal of Medicine.

Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival.

A. Howell, R. Gelber, A. Goldhirsch, 1995, The cancer journal from Scientific American.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

J. Forbes, F. Cavalli, R. Gelber, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

International Consensus Panel on the treatment of primary breast cancer. V: Update 1998.

R. Gelber, A. Goldhirsch, J. Glick, 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Evaluating the Benefits of Therapies for Breast Cancer

R. Gelber, A. Goldhirsch, 1987 .

Occult axillary lymph-node micrometastases in breast cancer

R. Gelber, A. Goldhirsch, A. Neville, 1990, The Lancet.

Axillary node micrometastases and breast cancer

R. Gelber, A. Goldhirsch, K. Price, 1991, The Lancet.

Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

J. Forbes, R. Gelber, A. Goldhirsch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better?

R. Gelber, M. Colleoni, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First repeated bone scan in the observation of patients with operable breast cancer.

R. Gelber, A. Goldhirsch, M. Castiglione, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

R. Gelber, L. Mofenson, C. Rouzioux, 2002, The Journal of infectious diseases.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

E. Perez, R. Gelber, G. Viale, 2014, Breast Cancer Research and Treatment.

Alternative Methods for Describing Treatment Benefit Including Quality-of-Life Considerations

R. Gelber, A. Goldhirsch, 1991 .

The influence of surgery and radiation therapy on patients with brain metastases.

R. Gelber, M. S. Lee, F. Hendrickson, 1983, International journal of radiation oncology, biology, physics.

Radiotherapy and chemotherapy in high-risk breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 1998, The New England journal of medicine.

Can a clinical trial be the treatment of choice for patients with cancer?

R. Gelber, A. Goldhirsch, 1988, Journal of the National Cancer Institute.

A controlled evaluation of combined radiation and bleomycin therapy for squamous cell carcinoma of the esophagus.

J. Earle, R. Gelber, R. Hahn, 1980, International journal of radiation oncology, biology, physics.

Prognostic importance of thymidylate synthase expression in early breast cancer.

R. Gelber, B. Gusterson, P. Johnston, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer: Anastrozole and fulvestrant—combination to unlock efficacy

R. Gelber, A. Goldhirsch, 2012, Nature Reviews Clinical Oncology.

Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group.

R. Gelber, L. Lowry, J. Snow, 1987, Head & neck surgery.

Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX

R. Gelber, A. Goldhirsch, F. Cardoso, 2010 .

Radiotherapy to the conserved breast: is it avoidable if the cancer is small?

R. Gelber, A. Goldhirsch, 1994, Journal of the National Cancer Institute.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Analyzing local and distant recurrence (Reply)

R. Gelber, C. Coleman, R. Gelman, 1990 .

Meeting highlights: international consensus panel on the treatment of primary breast cancer.

R. Gelber, A. Goldhirsch, J. Glick, 2002, Journal of the National Cancer Institute.

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

R. Gelber, A. Goldhirsch, J. Glick, 1995, Journal of the National Cancer Institute.

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos

R. Gelber, M. Piccart, G. Viale, 2020 .

Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2012 .

Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.

R. Gelber, L. Mofenson, M. Newell, 2004, American journal of obstetrics and gynecology.

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index

R. Gelber, A. Goldhirsch, A. Coates, 2005, The Lancet.

Who gets chemotherapy for metastatic lung cancer?

M. Weinstein, C. Earle, R. Gelber, 2000, Chest.

Impact of referral patterns on the use of chemotherapy for lung cancer.

M. Weinstein, C. Earle, R. Gelber, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensified therapy for infants with acute lymphoblastic leukemia

R. Gelber, S. Sallan, L. Silverman, 1997, Cancer.

Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)

R. Gelber, A. Goldhirsch, M. Castiglione, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316

R. Gelber, L. Mofenson, J. Sullivan, 2004, Journal of acquired immune deficiency syndromes.

Reporting and interpreting adjuvant therapy clinical trials. International Breast Cancer Study Group (formerly Ludwig Group).

R. Gelber, A. Goldhirsch, 1992, Journal of the National Cancer Institute. Monographs.

Reporting and interpreting adjuvant therapy clinical trials

R. Gelber, A. Goldhirsch, 1992 .

Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.

G. Parmigiani, R. Gelber, L. Trippa, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using clinical trial data to tailor adjuvant treatments for individual patients.

R. Gelber, M. Regan, 2007, Breast.

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

R. Gelber, A. Goldhirsch, F. Cardoso, 2012, British Journal of Cancer.

Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V.

R. Gelber, A. Goldhirsch, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Perioperative and conventionally timed chemotherapy in operable breast cancer: the Ludwig Breast Cancer Study V.

R. Gelber, A. Goldhirsch, 1986, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.

E. Winer, R. Gelber, M. Piccart, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trials of Adjuvant Chemotherapy for Operable Breast Cancer

R. Gelber, A. Goldhirsch, 1991 .

Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia.

R. Gelber, S. Sallan, N. Tarbell, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up

M. Dowsett, R. Gelber, J. Baselga, 2012 .

Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer.

R. Gelber, A. Goldhirsch, J. Glick, 1995, European journal of cancer.

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

R. Gelber, M. Piccart, J. Lee, 2021, Breast.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821.

R. Gelber, Y. Ravindranath, S. Gelber, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: R.T.O.G. brain metastases phases I & II

R. Gelber, J. Cooper, H. Berry, 1978 .

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

E. Winer, R. Gelber, L. Trippa, 2022, NPJ breast cancer.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

R. Gelber, J. Baselga, M. Ignatiadis, 2018, Cancer.

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

R. Gelber, M. Gnant, A. Goldhirsch, 2018, International journal of radiation oncology, biology, physics.

The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study.

R. Gelber, L. Brady, T. Griffin, 1978, International journal of radiation oncology, biology, physics.

Early studies establishing the predictive and prognostic value of steroid hormone receptors measured levels of ER and PgR in Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006 .

Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Cancer.

Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

A. Giobbie-Hurder, P. Neven, R. Gelber, 2020, Breast Cancer Research and Treatment.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

Adjuvant Systemic Therapy for Breast Cancer Patients Without Lymph Node Metastases (N

R. Gelber, A. Goldhirsch, 1989 .

IBCSG's reply

R. Gelber, A. Goldhirsch, M. Castiglione, 1993, The Lancet.

Randomized Preoperative and Postoperative Radiation Therapy for Patients with Carcinoma of the Head and Neck: Preliminary Report

R. Gelber, L. Lowry, J. Snow, 1980, The Laryngoscope.

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Per Karlsson, Zhuoxin Sun, J. Forbes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2004, British Journal of Cancer.

Subpopulation Treatment Effect Pattern Plot (Stepp) Method with R and Stata

M. Bonetti, R. Gelber, B. Cole, 2022, SSRN Electronic Journal.

Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, B. Cole, 1993, Cancer treatment reviews.

Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al

R. Gelber, J. Bernhard, M. Regan, 2017, Quality of Life Research.

The Legacy of Professor Aron Goldhirsch.

E. Winer, R. Gelber, M. Piccart, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer.

R. Gelber, S. Gelber, A. Partridge, 2017, Journal of adolescent and young adult oncology.

Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials

G. Giaccone, R. Gelber, C. Specchia, 2022, JAMA network open.

lymphoblastic leukemia Cell surface antigens: prognostic implications in childhood acute

R. Gelber, S. Sallan, J. Ritz, 2011 .

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.

R. Gelber, C. Hürny, J. Bernhard, 1998, Statistics in Medicine.

Comparison of Adjuvant Therapies Using Quality-Of-Life Considerations

R. Gelber, A. Goldhirsch, 1989, International Journal of Technology Assessment in Health Care.

Chemotherapy of advanced esophageal carcinoma: Eastern cooperative oncology group experience

R. Gelber, R. Hahn, C. Moertel, 1980, Cancer.

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

E. Perez, R. Gelber, S. Martino, 2014, Journal of Clinical Oncology.

Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Radiation therapy oncology group brain metastases study I and II

R. Gelber, J. Cooper, H. Berry, 1980, Cancer.

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

R. Gelber, M. Piccart, N. Pondé, 2019, npj Breast Cancer.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.

R. Gelber, A. Goldhirsch, K. Price, 2009, Breast.

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 1997, Annals of Oncology.

Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective.

R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

James N Ingle, E. Winer, T. Powles, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery Radiation Therapy Oncology Group study (76–16)

R. Gelber, L. Gunderson, C. Rominger, 1985, American journal of clinical oncology.

Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype

R. Gelber, M. Dyer, B. Gusterson, 1994 .

Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.

R. Gelber, M. Link, H. Grier, 1992, Leukemia.

Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

R. Gelber, N. Wolmark, J. Nortier, 2012 .

Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia.

R. Gelber, A. Spirito, R. Drigan, 1992, Medical and pediatric oncology.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

R. Gelber, M. Piccart, J. Baselga, 2021, British Journal of Cancer.

Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276).

R. Gelber, C. Danjoux, D. Klaassen, 1985, International journal of radiation oncology, biology, physics.

Endocrine Aspects in Adjuvant Therapy for Early Breast Cancer

R. Gelber, A. Goldhirsch, H. Mouridsen, 1986 .

A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group).

R. Gelber, A. Goldhirsch, M. Castiglione, 1992, Journal of the National Cancer Institute. Monographs.

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.

M. Zelen, R. Gelber, A. Goldhirsch, 1985, Cancer research.

MENSTRUAL EFFECT ON SURGICAL CURE OF BREAST CANCER

T. Powles, R. Gelber, A. Goldhirsch, 1989, The Lancet.

Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

R. Gelber, J. Baselga, Bing-he Xu, 2013 .

Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).

R. Gelber, A. Goldhirsch, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.

R. Gelber, M. Regan, A. Partridge, 2018 .

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

R. Gelber, A. Goldhirsch, G. Viale, 2018, The Lancet. Oncology.

Adjuvant Chemotherapy in Premenopausal Patients: A More Complicated Form of Oophorectomy?

R. Gelber, A. Goldhirsch, H. Mouridsen, 1987 .

Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy

R. Gelber, A. Goldhirsch, G. Viale, 2010, Breast Cancer Research and Treatment.

Improved methodology for analyzing local and distant recurrence.

R. Gelber, C. Coleman, R. Gelman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

R. Gelber, M. Buyse, M. Piccart, 2022, JAMA oncology.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2005, The New England journal of medicine.

Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.

R. Gelber, A. Goldhirsch, 1986, NCI monographs : a publication of the National Cancer Institute.

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.

M. Tattersall, R. Gelber, A. Goldhirsch, 1997, European journal of cancer.

Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.

R. Gelber, A. Goldhirsch, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Endocrine therapies of breast cancer.

R. Gelber, A. Goldhirsch, Gelber Rd, 1996, Seminars in oncology.

Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708)

R. Gelber, G. Viale, M. Piccart-Gebhart, 2010 .

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.

R. Gelber, S. Sallan, L. Silverman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.

R. Gelber, M. Link, H. Weinstein, 1987, Haematology and blood transfusion.

Meeting highlights: international consensus panel on the treatment of primary breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2002, Journal of the National Cancer Institute.

More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.

R. Gelber, S. Sallan, H. Cohen, 1990, Haematology and blood transfusion.

Dentofacial development in long‐term survivors of acute lymphoblastic leukemia: A comparison of three treatment modalities

R. Gelber, S. Sallan, N. Tarbell, 1990, Cancer.

Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to escherichia coli asparaginase

R. Gelber, S. Sallan, A. Billett, 1992, Cancer.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

R. Gelber, R. Sperling, E. Connor, 1994, The New England journal of medicine.

Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials.

R. Gelber, T. Chalmers, A. Liberati, 1986, JAMA.

Reduction of maternal-infant transmission of human immunodeficiency virus 1 with zidovudine treatment

Robert W. Coombs, Pavel Kiselev, Jack Moye, 1995 .

Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct.

R. Gelber, A. Goldhirsch, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.

P. Volberding, R. Gelber, A. Goldhirsch, 1994, The New England journal of medicine.

Estimation in regression models for longitudinal binary data with outcome-dependent follow-up.

Joseph G Ibrahim, Stuart R Lipsitz, Garrett M Fitzmaurice, 2005, Biostatistics.

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

A. Luini, R. Gelber, A. Goldhirsch, 2013, The Lancet. Oncology.

Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial.

R. Gelber, R. Ruben, K. Price, 1988, The New England journal of medicine.

Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update

R. Gelber, D. Rosenthal, R. Mayer, 1983 .

Endocrine therapy of breast cancer.

R. Gelber, A. Goldhirsch, M. Colleoni, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Richard Bell, Mitch Dowsett, 2017, The Lancet.

Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck?: A radiation therapy oncology group report

R. Gelber, J. Snow, S. Kramer, 1982, Cancer.

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

R. Gelber, J. Kirkwood, A. Goldhirsch, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.

R. Gelber, S. Sallan, J. Cassady, 1983, Cancer research.

Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.

R. Gelber, D. Hedley, C. Rugg, 1987, Cancer research.

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central nervous system treatment in childhood acute lymphoblastic leukemia. Long‐term follow‐up of patients diagnosed between 1973 and 1985

R. Gelber, S. Sallan, N. Tarbell, 1993, Cancer.

"Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type I with Zidovudine Treatment."

R. Gelber, R. Sperling, E. Connor, 1994 .

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

R. Gelber, N. McGrath, S. Spector, 1994, The New England journal of medicine.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Intensive sequential chemotherapy for children with acute myelogenous leukemia.

R. Gelber, M. Link, H. Weinstein, 1990, Haematology and blood transfusion.

LATE EFFECTS OF CENTRAL NERVOUS SYSTEM TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD ARE SEX‐DEPENDENT

R. Gelber, S. Sallan, N. Tarbell, 1990, Developmental medicine and child neurology.

Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.

R. Gelber, S. Sallan, L. Cohen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group.

R. Gelber, W. Borkowsky, M. Fowler, 1996, The Journal of infectious diseases.

Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.

R. Gelber, L. Mofenson, M. Newell, 2002, JAMA.

Concentrations of protease inhibitors in cord blood after in utero exposure

R. Gelber, L. Mofenson, J. Connor, 2002, The Pediatric infectious disease journal.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

M. Dowsett, R. Gelber, D. Larsimont, 2018, Clinical Cancer Research.

Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.

M. Bonetti, R. Gelber, A. Goldhirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence

R. Gelber, A. Goldhirsch, G. Viale, 2019, Breast Cancer Research.

Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.

R. Gelber, D. Coppola, S. Sallan, 1999, Journal of pediatric hematology/oncology.

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

C. Pui, R. Gelber, E. Korn, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

D. Neuberg, R. Gelber, S. Sallan, 2007, Blood.

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

R. Gelber, D. Cameron, M. Piccart-Gebhart, 2013, The Lancet. Oncology.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

R. Gelber, A. Goldhirsch, G. Pruneri, 2016, Breast Cancer Research and Treatment.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

METHOTREXATE/NITROUS-OXIDE TOXIC INTERACTION IN PERIOPERATIVE CHEMOTHERAPY FOR EARLY BREAST CANCER

F. Cavalli, R. Gelber, A. Goldhirsch, 1987, The Lancet.

Induction failure in acute lymphoblastic leukemia of childhood

R. Gelber, S. Sallan, L. Silverman, 1999, Cancer.

Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols.

R. Gelber, S. Sallan, C. Niemeyer, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

R. Gelber, S. Sallan, N. Tarbell, 1986, The New England journal of medicine.

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

R. Gelber, S. Sallan, N. Tarbell, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia.

R. Gelber, S. Sallan, J. Ritz, 1980, Blood.

Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

R. Gelber, S. Sallan, L. Silverman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bony M orbidity i n C hildren T reated f or A cute Lymphoblastic L eukemia

R. Gelber, S. Sallan, L. Silverman, 2001 .

The AURORA initiative for metastatic breast cancer

C Sotiriou, C. Sotiriou, M. Dowsett, 2014, British Journal of Cancer.

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion

G. Giaccone, R. Gelber, C. Swanton, 2021, Clinical Cancer Research.

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial

M. Dowsett, R. Gelber, J. Baselga, 2019, AntiCancer Research.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of Clinical Oncology.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Sally Hunsberger, R. Gray, R. Gelber, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia.

R. Gelber, J. Fletcher, S. Sallan, 1989, Blood.

Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis

R. Gelber, A. Goldhirsch, C. Rudenstam, 1986, Cancer.

Adjuvant Therapy of Breast Cancer V

R. Gelber, A. Goldhirsch, B. Thürlimann, 1996, Recent Results in Cancer Research.

Adjuvant Therapy of Breast Cancer IV

R. Gelber, A. Goldhirsch, B. Thürlimann, 1993, Recent Results in Cancer Research.

The treatment of acute myelogenous leukemia in children and adults: VAPA update.

R. Gelber, D. Rosenthal, R. Mayer, 1983, Haematology and blood transfusion.

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

A. Giobbie-Hurder, R. Gelber, T. Ahern, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in medulloblastoma, including DNA ploidy.

R. Gelber, S. Sallan, P. Barnes, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas.

R. Gelber, J. Horton, C. Moertel, 1981, Cancer treatment reports.

Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.

R. Gelber, D. Rosenthal, R. Mayer, 1983, Blood.

Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.

R. Gelber, A. Goldhirsch, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

R. Gelber, A. Goldhirsch, R D Gelber, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole‐abdominal radiotherapy

R. Gelber, E. Dreher, A. Goldhirsch, 1988, Cancer.

Ki‐67 expression in breast carcinoma

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial

Patrick Neven, Benjamin Haibe-Kains, Christine Desmedt, 2009, BMC Medical Genomics.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pregnancy after breast cancer: if you wish, ma’am

R. Gelber, A. Goldhirsch, S. Badve, 2011, Breast Cancer Research and Treatment.

INTENSIVE POST-REMISSION INDUCTION CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA IN CHILDREN AND ADULTS

R. Gelber, D. Rosenthal, R. Mayer, 1984 .

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia

R. Gelber, S. Sallan, S. Kreissman, 1992, Cancer.

Adjuvant Therapy of Primary Breast Cancer

R. Gelber, J. Glick, H. Senn, 1989 .

Treatment of breast cancer in elderly patients

R. Gelber, R. Gelman, A. Goldhirsch, 1990, The Lancet.

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).

R. Gelber, G. Hortobagyi, L. Minasian, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy of Primary Breast Cancer VI

R. Gelber, H. Senn, 1998, Recent Results in Cancer Research.

Adjuvant therapy for very young women with breast cancer: need for tailored treatments.

R. Gray, R. Gelber, J. Bryant, 2001, Journal of the National Cancer Institute. Monographs.

Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect o f P regnancy o n O verall S urvival A fter t he Diagnosis o f E arly-Stage B reast C ancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

R. Gelber, D. Larsimont, M. Buyse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

E J Orav, S R Lipsitz, S. Lipsitz, 1995, The New England journal of medicine.

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

R. Gelber, M. Piccart, H. Gómez, 2022, European journal of cancer.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

R. Gelber, J. Baselga, T. Hickish, 2019, European journal of cancer.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group.

R. Gelber, J. Cooper, L. Brady, 1981, International journal of radiation oncology, biology, physics.

Prognostic factors in childhood acute myelogenous leukemia.

R. Gelber, K. Price, M. Link, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials for clinicians.

R. Gelber, A. Goldhirsch, 1989, Chest.

Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression

R. Gelber, A. Goldhirsch, G. Pruneri, 2008, Cancer Chemotherapy and Pharmacology.

Reporting Results from Adjuvant Therapy Trials with Special Emphasis on Quality-of-Life Findings

R. Gelber, A. Goldhirsch, M. Castiglione, 1992 .

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.

M. Zelen, R. Gelber, A. Goldhirsch, 1989, The New England journal of medicine.

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.

P Glasziou, R. Gelber, P. Glasziou, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

A. Giobbie-Hurder, J. Forbes, P. Neven, 2013, Breast Cancer Research and Treatment.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

J. Forbes, R. Gelber, A. Goldhirsch, 2009, Breast Cancer Research and Treatment.

Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.

R. Gelber, A. Goldhirsch, A. Coates, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

R. Gelber, A. Goldhirsch, D. Zahrieh, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2003, Journal of the National Cancer Institute.

Treatment o f C hildhood A cute L ymphoblastic L eukemia: Results o f D ana-Farber A LL C onsortium P rotocol 8 7-01

R. Gelber, S. Sallan, L. Silverman, 2002 .

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.

R. Gelber, S. Sallan, L. Silverman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–

J. Forbes, R. Gelber, A. Goldhirsch, 2001 .

Influence o f E ndocrine-Relate d F actors o n R esponse t o Perioperative C hemotherapy f or P atients W ith N ode- Negative B reast C ancer

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Breast Cancer Trials of the Ludwig and International Breast Cancer Study Group

J. Forbes, R. Gelber, A. Goldhirsch, 1987 .

Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients.

R. Gelber, N. Jaffe, M. Link, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

A. Giobbie-Hurder, R. Gelber, B. Gusterson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

R. Gelber, M. Piccart, P. Arnone, 2023, Breast.

Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis

R. Gelber, S. Kramer, B. Borgelt, 1981, Cancer.

Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia

R. Gelber, S. Sallan, J. Ritz, 1993 .

Autologous bone marrow transplantation for acute lymphoblastic leukemia.

R. Bast, R. Gelber, S. Sallan, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pediatric histiocytosis. Characterization, prognosis, and oral involvement.

R. Gelber, R. Arceci, M. Donnelly, 1993, The American journal of pediatric hematology/oncology.

Second malignancies in patients treated for childhood acute lymphoblastic leukemia.

R. Gelber, S. Sallan, N. Tarbell, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ophthalmic evaluation of survivors of acute lymphoblastic leukemia.

Lois E. H. Smith, R. Gelber, S. Sallan, 1988, Ophthalmology (Rochester, Minn.).

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, The Lancet. Oncology.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

P. Neven, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

M. Bonetti, R. Gelber, A. Goldhirsch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA

R. Gelber, L. Mandelbrot, M. Newell, 2007, BMC infectious diseases.

Predose Infant Nevirapine Concentration With the Two‐Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose

R. Gelber, L. Mofenson, S. Blanchard, 2003, Journal of acquired immune deficiency syndromes.

Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia

R. Gelber, S. Sallan, M. Levin, 1985, Pediatric infectious disease.

Challenges of guarantee-time bias.

A. Giobbie-Hurder, R. Gelber, M. Regan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meeting H ighlights: U pdated I nternational E xpert C onsensus on t he P rimary T herapy o f E arly B reast C ancer

R. Gelber, A. Goldhirsch, A. Coates, 2003 .

Meet ing Highl ights : Updated Internat ional Expert Consensus on the Primary Therapy of Early Breast Cancer

R. Gelber, A. Coates, B. Thürlimann, 2003 .

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

R. Gelber, A. Goldhirsch, A. Coates, 2001, The Lancet.

COMMENTARY Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

R. Gelber, A. Goldhirsch, J. Glick, 1998 .

International Consensus Panel on the Treatment of Primary Breast Cancer V: Update 1998

R. Gelber, A. Goldhirsch, J. Glick, 1998 .

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

A. Luini, R. Gelber, A. Goldhirsch, 2009, Breast Cancer Research and Treatment.

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198

P. Neven, R. Gelber, B. Gusterson, 2007 .

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

B. Bonanni, R. Gelber, A. Goldhirsch, 2016, Breast Cancer Research.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tailoring adjuvant treatments for the individual breast cancer patient.

M. Bonetti, R. Gelber, A. Goldhirsch, 2003, Breast.

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

J. Forbes, R. Gelber, R. Paridaens, 2005 .

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, R. Gelber, A. Goldhirsch, 1998, European journal of cancer.

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

J. Forbes, R. Gelber, A. Goldhirsch, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.

M. Zelen, R. Gelber, B. Gusterson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.

R. Gelber, A. Goldhirsch, A. Coates, 2003, Breast.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant endocrine therapy for premenopausal women with early breast cancer.

R. Gelber, A. Goldhirsch, M. Colleoni, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial.

R. Gelber, A. Goldhirsch, C. Hürny, 1996, Medical care.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

J. Forbes, R. Gelber, B. Gusterson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

J. Bergh, R. Gelber, J. Klijn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

R. Gelber, A. Goldhirsch, G. MacGrogan, 2015, Breast Cancer Research and Treatment.

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

R. Gelber, A. Goldhirsch, J. Bernhard, 2015, The Lancet. Oncology.

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

E. Winer, R. Gelber, M. Piccart-Gebhart, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Mitch Dowsett, Marion Procter, Brian Leyland-Jones, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Facilitating consensus by examining patterns of treatment effects.

R. Gelber, S. Gelber, 2009, Breast.

15 Timing of radiotherapy (RT) and chemotherapy (CT) following breast conserving surgery (BCS) for patients with node-positive breast cancer

R. Gelber, M. Castiglione‐Gertsch, J. Bernier, 1995 .

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

R. Gelber, A. Goldhirsch, F. Cardoso, 2015, Breast.

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.

C. Sotiriou, M. Dowsett, R. Gelber, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D

M. Bonetti, R. Gelber, D. Zahrieh, 2010, Breast Cancer Research and Treatment.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood

R. Gelber, N. Tarbell, P. Mauch, 1993, The Lancet.

The role of radiation therapy in the palliation of metastatic genitourinary tract carcinomas. A study of the radiation therapy oncology group

R. Gelber, S. Reddy, F. Hendrickson, 2006, Cancer.

Comparison of preoperative and postoperative radiation therapy for patients with carcinoma of the head and neck. Interim report.

R. Gelber, L. Lowry, J. Snow, 1981, Acta oto-laryngologica.

Evaluation of Randomized Preoperative and Postoperative Radiation Therapy for Supraglottic Carcinoma

R. Gelber, L. Lowry, J. Snow, 1978, The Annals of otology, rhinology, and laryngology.

Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

R. Gelber, T. Griffin, B. Borgelt, 1981, International journal of radiation oncology, biology, physics.

Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".

R. Gelber, P. Lavin, P. Carbone, 1979, Surgery.

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

R. Gelber, D. Zardavas, M. Piccart-Gebhart, 2019, Breast Cancer Research and Treatment.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

S. Lipsitz, S. Colan, R. Gelber, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiemetic Effect of Intramuscular Levonantradol in Patients Receiving Anticancer Chemotherapy

R. Gelber, S. Sallan, J. Laszlo, 1981, Journal of clinical pharmacology.

Sex and cancer immunotherapy: Current understanding and challenges.

G. Giaccone, R. Gelber, S. Minucci, 2022, Cancer cell.

IX. International consensus conference on primary treatment of breast cancer.

R. Gelber, A. Goldhirsch, J. Glick, 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 2009, European journal of cancer.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

R. Gelber, C. Specchia, G. Viale, 2021, BMJ.

Quality adjusted survival analysis with repeated quality of life measures.

J Hilden, J. Hilden, R. Gelber, 1998, Statistics in medicine.

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.

R. Gelber, H. Wieand, A. Goldhirsch, 1996, Journal of the National Cancer Institute.

Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST Method

R. Gelber, A. Goldhirsch, S. Gelber, 1995 .

Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

R. Gelber, H. Gómez, A. Goldhirsch, 2018 .

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

R. Gelber, S. Martino, A. Goldhirsch, 2018 .

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.

R. Gelber, S. Sallan, E. Thompson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method.

R. Gelber, C. Schwartz, B. Cole, 1995, Archives of neurology.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

R. Gelber, A. Tutt, J. Garber, 2017 .

New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?

R. Gelber, A. Goldhirsch, A. Coates, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Meta-analysis in clinical research.

R. Gelber, A. Goldhirsch, 1988, Annals of internal medicine.

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, W. McCaskill-Stevens, P. Francis, 2009, Breast Cancer Research and Treatment.

Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012 .

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

C. Sotiriou, R. Gelber, M. Piccart, 2020, Breast Cancer Research and Treatment.

Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.

R. Gelber, A. Goldhirsch, J. Collins, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Life with consequences of breast cancer: pregnancy during and after endocrine therapies.

R. Gelber, A. Goldhirsch, 2004, Breast.

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors

A. Luini, R. Gelber, A. Goldhirsch, 2004, Clinical Cancer Research.

Preoperative systemic treatment: prediction of responsiveness.

A. Luini, R. Gelber, A. Goldhirsch, 2003, Breast.

Overhauling the breast cancer overview: are subsets subversive?

R. Gelber, A. Goldhirsch, A. Coates, 2002, The Lancet. Oncology.

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF

M. Bonetti, R. Gelber, W. Sauerbrei, 2002, British Journal of Cancer.

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.

R. Gelber, A. Goldhirsch, J. Bernhard, 2010, Breast.

Evaluation of Quality of Life in Cancer Clinical Trials

R. Gelber, S. Gelber, B. Cole, 2001 .

Methodology of Clinical Trials. Investigating Endocrine Mechanisms in Breast Cancer

R. Gelber, A. Goldhirsch, 1986 .

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

R. Gelber, H. Gómez, A. Goldhirsch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Principles of clinical trials

M. Bonetti, R. Gelber, E. Eisenhauer, 1999 .

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

A. Luini, R. Gelber, A. Goldhirsch, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Cox regression models for quality adjusted survival analysis.

R. Gelber, A. Goldhirsch, B. Cole, 1993, Statistics in medicine.

Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.

R. Gelber, A. Goldhirsch, M. Castiglione, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.

J. Forbes, M. Bonetti, R. Gelber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

J. Forbes, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy of primary breast cancer: closing summary.

R. Gelber, A. Goldhirsch, J. Glick, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Meeting highlights: adjuvant therapy for primary breast cancer.

R. Gelber, A. Goldhirsch, J. Glick, 1992, Journal of the National Cancer Institute.

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.

E. Winer, R. Gelber, A. Goldhirsch, 2007, European journal of cancer.

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

M. Dowsett, R. Gelber, J. Baselga, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013 .

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

R. Gelber, M. Piccart, N. Pondé, 2019, npj Breast Cancer.

Effect of systemic adjuvant treatment on first sites of breast cancer relapse

G Marini, M. Tattersall, J. Forbes, 1994, The Lancet.

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

R. Gelber, B. Gusterson, A. Goldhirsch, 2012, Breast Cancer Research.

How to improve timing and duration of adjuvant chemotherapy

R. Gelber, A. Coates, M. Castiglione‐Gertsch, 2001 .

Meeting H ighlights: I nternational C onsensus P anel o n t he Treatment o f P rimary B reast C ancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

R. Gelber, A. Goldhirsch, A. Coates, 2002 .

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.

R. Gelber, M. Piccart, G. Viale, 2019, Journal of Clinical Oncology.

Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1996, International journal of radiation oncology, biology, physics.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

A quality-of-life-oriented endpoint for comparing therapies.

R. Gelber, R. Gelman, A. Goldhirsch, 1989, Biometrics.

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

R. Gelber, A. Goldhirsch, J. Bernhard, 2011, Breast Cancer Research and Treatment.

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

A. Giobbie-Hurder, R. Gelber, A. Goldhirsch, 2020, Breast Cancer Research and Treatment.

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

S. Lipsitz, S. Colan, R. Gelber, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione, 1992, European journal of cancer.

The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

J. Forbes, R. Gelber, A. Goldhirsch, 2008, Breast Cancer Research and Treatment.

Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011 .

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

R. Gelber, M. Piccart, J. Costantino, 2008, Clinical breast cancer.

Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, M. Castiglione, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P82 Tailored chemotherapy trial for women at advancedage with endocrine nonresponsive breast cancer: the CASA Trial

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 2005 .

Predicting response to systemic treatments: learning from the past to plan for the future.

R. Gelber, M. Regan, Meredith M Regan, 2005, Breast.

Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.

M. Weinstein, C. Earle, R. Gelber, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The concept of an overview of cancer clinical trials with special emphasis on early breast cancer.

R. Gelber, A. Goldhirsch, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer

F. Cavalli, R. Gelber, A. Goldhirsch, 1991 .

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach

R. Gelber, A. Goldhirsch, C. Hürny, 1998 .

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII.

R. Gelber, A. Goldhirsch, M. Castiglione, 2016, International journal of radiation oncology, biology, physics.

Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes

Xin Victoria Wang, Marco Bonetti, Wai-Ki Yip, 2016, Clinical trials.

A small sample study of the STEPP approach to assessing treatment–covariate interactions in survival data

Marco Bonetti, M. Bonetti, R. Gelber, 2009, Statistics in medicine.

Taxanes as adjuvant for breast cancer

R. Gelber, A. Goldhirsch, P. Francis, 2000, The Lancet.

Quality of life scores predict outcome in metastatic but not in early breast cancer

R. Gelber, A. Goldhirsch, C. Hürny, 2001 .

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

R. Gelber, A. Goldhirsch, J. Collins, 2009, Breast Cancer Research and Treatment.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

J. Forbes, R. Gelber, P. Maruff, 2016, British Journal of Cancer.

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Models for weighing benefits and toxicities.

R. Gelber, A. Goldhirsch, 1992, Cancer treatment and research.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

R. Gelber, A. Goldhirsch, A. Coates, 2014, Breast Cancer Research and Treatment.

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations☆

C. Sotiriou, R. Gelber, M. Piccart, 2021, Breast.

Adjuvant therapy in postmenopausal node-positive breast cancer.

M. Tattersall, F. Cavalli, R. Gelber, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methodological and statistical aspects in perioperative chemotherapy trials.

R. Gelber, 1985, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high‐risk acute lymphoblastic leukemia

R. Gelber, S. Sallan, L. Silverman, 2001, Cancer.

Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The open questions

R. Gelber, A. Goldhirsch, A. Coates, 2003 .

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

R. Gelber, S. Loi, F. Cardoso, 2022, European journal of cancer.

Reply to D. Serraino et al.

R. Gelber, S. Gelber, A. Partridge, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

M. Bonetti, R. Gelber, B. Cole, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

R. Gelber, M. Piccart, J. Baselga, 2015, Breast Cancer Research and Treatment.

Interpretation of results from subset analyses within overviews of randomized clinical trials.

R. Gelber, A. Goldhirsch, R D Gelber, 1987, Statistics in medicine.

Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses.

R. Gelber, A. Goldhirsch, A. Coates, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

The Q-TWiST approach to assessing health-related quality of life in epilepsy

R. Gelber, C. Schwartz, B. Vickrey, 1995, Quality of Life Research.

Evaluation of effectiveness: Q-TWiST

R. Gelber, A. Goldhirsch, B. Cole, 1993 .

How to compare quality of life of breast cancer patients in clinical trials. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, B. Cole, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group.

M A Fischl, R. Gelber, A. Goldhirsch, 1992, Annals of internal medicine.

Adjuvant therapy of breast cancer

R. Gelber, A. Goldhirsch, M. Castiglione, 1991 .

CHEMOENDOCRINE VERSUS ENDOCRINE THERAPY IN BREAST CANCER

J. Silber, R. Gelber, A. Goldhirsch, 1984, The Lancet.

Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovarian Function Suppression

R. Gelber, A. Goldhirsch, M. Castiglione, 1990 .

Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.

E. Perez, R. Gelber, L. Hartmann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.

R. Gelber, F. de Marinis, A. Goldhirsch, 2019, Journal of the National Cancer Institute.

A Quality-Adjusted Survival (Q-TWiST) Model for Evaluating Treatments for Advanced Stage Cancer

R. Gelber, S. Gelber, B. Cole, 2004, Journal of biopharmaceutical statistics.

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

E. Winer, R. Gelber, S. Loi, 2022, Cancer Research.

Meta‐STEPP: subpopulation treatment effect pattern plot for individual patient data meta‐analysis

Xin Victoria Wang, Marco Bonetti, M. Bonetti, 2016, Statistics in medicine.

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes-waiting for TAILORx and RxPONDER.

C. Perou, R. Gelber, M. Cheang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

R. Gelber, A. Goldhirsch, G. Viale, 2018, Breast Cancer Research and Treatment.

Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer.

R. Gelber, S. Taylor, 1982, Cancer treatment reports.

Systemic treatments for women with breast cancer: outcome with relation to screening for the disease.

R. Gelber, A. Goldhirsch, M. Colleoni, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Parametric approaches to quality adjusted survival analysis

R. Gelber, K. Anderson, B. Cole, 1992 .

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

R. Gelber, A. Goldhirsch, J. Bernhard, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies in adjuvant systemic therapy of breast cancer: Introduction

R. Gelber, A. Goldhirsch, M. Piccart-Gebhart, 2002 .

Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer

R. Gelber, F. Cardoso, M. Piccart-Gebhart, 2002 .

Developing an international network for breast cancer research: the BIG experience

M. Dowsett, R. Gelber, J. Baselga, 2011 .

A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.

R. Gelber, A. Goldhirsch, G. Viale, 2012, Breast.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

R. Gelber, S. Aebi, 2009, The New England journal of medicine.

Timing breast cancer surgery

J. Forbes, R. Gelber, R. Blamey, 1991, The Lancet.

Tailoring treatments for the individual patient

M. Bonetti, R. Gelber, A. Goldhirsch, 2003 .

R. Gelber, D. Feeny, S. Sallan, 2012, Pediatric blood & cancer.

Parameter Estimation in Longitudinal Studies with Outcome‐Dependent Follow‐Up

Joseph G Ibrahim, Stuart R Lipsitz, Garrett M Fitzmaurice, 2002, Biometrics.

Erratum to ''Preoperative systemic treatment: prediction of responsiveness'' The Breast 12(6) (2003) 538-542 $

A. Luini, R. Gelber, A. Goldhirsch, 2004 .

Effect of Pregnancy on Overal l Surv iva l Af ter the Diagnosis of Ear ly-Stage Breast Cancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

ENDOCRINE ADJUVANT THERAPY FOR BREAST CANCER

F. Cavalli, R. Gelber, A. Goldhirsch, 1985, The Lancet.

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO Trial.

R. Gelber, J. Baselga, M. Piccart-Gebhart, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Another STEPP in the right direction.

Marco Bonetti, M. Bonetti, R. Gelber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomized trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate and 5-fluorouracil)

M. Bonetti, R. Gelber, W. Sauerbrei, 2002 .

Prognostic value of Helix pomatia in breast cancer. International (Ludwig) Breast Cancer Study Group.

R. Gelber, M. Castiglione, H. Jayatilake, 1993, British Journal of Cancer.

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

for children with recurrent acute lymphoblastic leukemia Autologous bone marrow transplantation after a long first remission

R. Gelber, S. Sallan, J. Ritz, 2011 .

Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia.

R. Gelber, S. Sallan, J. Ritz, 1993, Blood.

S3-1: Update of International Breast Cancer Study Group Trial 23-01 To Compare Axillary Dissection Versus No Axillary Dissection in Patients with Clinically Node Negative Breast Cancer and Micrometastases in the Sentinel Node.

A. Luini, R. Gelber, A. Goldhirsch, 2011 .

Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)

R. Gelber, M. Piccart, J. Lee, 2023, Cancer Research.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

J. Forbes, R. Gelber, G. Hortobagyi, 2018, Journal of the National Cancer Institute.

Polychemotherapy for early breast cancer

R. Gelber, A. Goldhirsch, B. Cole, 2001, The Lancet.

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

R. Gelber, J. Baselga, M. Piccart-Gebhart, 2019 .

Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.

R. Gelber, A. Goldhirsch, G. Viale, 2020 .

A multistate Markov chain model for longitudinal, categorical quality‐of‐life data subject to non‐ignorable missingness

Marco Bonetti, Alan M Zaslavsky, A. Zaslavsky, 2005, Statistics in medicine.

A Method-of-Moments Estimation Procedure for Categorical Quality-of-Life Data with Nonignorable Missingness

M. Bonetti, R. Gelber, B. Cole, 1999 .

S37 Quality of life assessment in the adjuvant setting: Is it relevant?

M. Bonetti, R. Gelber, A. Goldhirsch, 1998 .

Quality of life assessment in the adjuvant setting: is it relevant? International Breast Cancer Study Group.

M. Bonetti, R. Gelber, A. Goldhirsch, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, B. Cole, 1995, Statistics in medicine.

Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V

E. Winer, R. Gelber, A. Goldhirsch, 2005 .

Adjuvant systemic therapy: the issues of timing and sequence.

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

Family History and Prognosis of Patients with Node-Positive Breast Cancer Treated with Adjuvant Therapy

R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, 1990 .

POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.

R. Gelber, M. Regan, A. Partridge, 2018 .

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis

M. Dowsett, R. Gelber, M. Piccart, 2016 .

The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, M. Buyse, W. McCaskill-Stevens, 2008 .

Features that predict responsiveness to chemotherapy and endocrine therapies

M. Bonetti, R. Gelber, A. Goldhirsch, 2001 .

Joint Regression Analysis of Survival and Quality‐Adjusted Survival

R. Gelber, J. Fine, J P Fine, 2001, Biometrics.

Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial

R. Gelber, M. Regan, A. Partridge, 2020, Breast.

Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer

R. Gelber, A. Goldhirsch, A. Coates, 2006, Cancer.

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

R. Gelber, A. Goldhirsch, G. Viale, 2012 .

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

R. Gelber, J. Baselga, Bing-he Xu, 2017 .

Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial

R. Bernards, R. Gelber, S. Loi, 2021 .

Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck? A Radiation Therapy Oncology Group Report.

R. Gelber, J. Snow, S. Kramer, 1981, Cancer.

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

R. Gelber, A. Goldhirsch, G. Viale, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.

M. Wulfsohn, R. Gelber, W. Borkowsky, 1991, The New England journal of medicine.

Bmc Medical Genomics the Gene Expression Grade Index: a Potential Predictor of Relapse for Endocrine-treated Breast Cancer Patients in the Big 1–98 Trial

A. Giobbie-Hurder, C. Sotiriou, P. Neven, 2022 .

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.

C. Perou, R. Gelber, M. Cheang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer

R. Gelber, A. Goldhirsch, A. Coates, 2001 .

Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.

R. Bast, R. Gelber, S. Sallan, 1985, Cancer research.

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

R. Gelber, A. Goldhirsch, A. Coates, 2000, The Lancet.

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

J L Sullivan, R. Gelber, S. Spector, 1996, The New England journal of medicine.

Analysis of survival by tumor response.

J R Anderson, James R. Anderson, R. Gelber, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

E. Winer, R. Gelber, G. Viale, 2021 .

Quality-of-life assessment in clinical trials.

R. Gelber, S. Gelber, R. Gelber, 1995, Cancer treatment and research.

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

R. Gelber, G. Viale, M. Regan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

c-erbB-2 protein expression in node negative breast cancer.

R. Gelber, B. Groner, A. Goldhirsch, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP

Marco Bonetti, Wai-Ki Yip, M. Bonetti, 2016, Clinical trials.

The Gene Expression Grade Index: A Potential Predictor of Relapse for Endocrine-treated Breast Cancer Patients in the BIG 1–98 Trial

A. Giobbie-Hurder, C. Sotiriou, P. Neven, 2022 .

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

J. Bergh, M. Dowsett, R. Gelber, 2023, Journal of Clinical Oncology.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study.

R. Gelber, D. Schoenfeld, 1979, Biometrics.

Are We RESPECTing Older Patients With Breast Cancer?

R. Gelber, E. de Azambuja, N. Pondé, 2020, Journal of Clinical Oncology.

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

R. Gelber, J. Baselga, G. Viale, 2018 .

Table of Contents

R. Gelber, A. Goldhirsch, M. Ernstoff, 2020, Annals of Oncology.

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

R. Gelber, M. Piccart, J. Baselga, 2019, Clinical breast cancer.

Trastuzumab after adjuvant chemotherapy in older patients – Authors' reply

R. Gelber, M. Piccart-Gebhart, M. Procter, 2007, The Lancet.

Trastuzumab after adjuvant chemotherapy in older patients - Reply

R. Gelber, M. Piccart-Gebhart, M. Procter, 2007 .

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

R. Gelber, B. Gusterson, A. Goldhirsch, 2012, Breast Cancer Research.

Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials.

R. Gelber, T. Chalmers, A. Liberati, 1986, JAMA.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.

A. Giobbie-Hurder, E. Winer, J. Forbes, 2013 .

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

R. Gelber, A. Tutt, M. Piccart, 2023, The Lancet.

Improved R esponse W ith H igher C orticosteroid D ose i n Children W ith A cute L ymphoblastic L eukemia

R. Gelber, S. Sallan, C. Schwartz, 2001 .

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

R. Gelber, M. Piccart, J. Lee, 2023, The New England journal of medicine.

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group).

F. Cavalli, R. Gelber, A. Goldhirsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.

J. Forbes, R. Gelber, A. Goldhirsch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, C. Hürny, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.

R. Gelber, S. Sallan, L. Silverman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant treatment for breast cancer: the overview.

R. Gelber, A. Goldhirsch, A. Coates, 1992, BMJ.

Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up

M. Dowsett, R. Gelber, M. Piccart, 2012 .

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

R. Gelber, J. Baselga, J. Mayordomo, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial (BIG 2-06/NCCTG N063D (Alliance)) ring study Ann E. McCulloughPatrizia Dell'OrtoMonica M. ReinholzRichard D. Gelber • Amylou C. DueckLeila RussoRobert B. JenkinsStefania Andrighetto •

R. Gelber, A. Dueck, M. Reinholz, 2014 .

Early S tart o f A djuvant C hemotherapy M ay I mprove Treatment O utcome f or P remenopausal B reast C ancer Patients W ith T umors n ot E xpressing E strogen R eceptors

M. Bonetti, R. Gelber, A. Coates, 2000 .

Adjuvant Therapy of Primary Breast Cancer

R. Gelber, Founding Editor, Rentchnick, 1989, Recent Results in Cancer Research.

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

R. Gelber, C. Specchia, F. Conforti, 2024, Frontiers in immunology.

Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.

R. Gelber, S. Minucci, V. Bagnardi, 2023, Seminars in oncology.

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Mode of delivery and the risk of vertical transmission of HIV-1.

R. Gelber, D. Shapiro, 1999, The New England journal of medicine.